Traws Pharma, Inc. Share Price & Technical Analysis
TRAW · $1.49 (0.00%)
Healthcare / Biotechnology
$1.49
0.00%
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxi…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
7% return in May, -5% avg return in past 3 year May month.
68% return in 2026, -23% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 91% | -20% | 13% | -22% | 7% | – | – | – | – | – | – | – | 68% |
| 25 | -18% | -54% | -28% | -32% | -7% | 7% | 0% | -7% | 46% | 37% | 4% | -59% | -111% |
| 24 | -7% | 15% | 23% | -35% | -12% | -21% | -11% | -6% | -40% | -14% | -8% | 93% | -22% |
| 23 | 89% | -34% | -12% | 62% | 4% | 4% | -10% | -25% | -13% | -19% | 9% | 9% | 63% |
| 22 | -24% | -17% | 7% | -26% | -14% | 10% | -9% | -3% | -27% | -22% | 17% | -22% | -131% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$27.42M
P/E ratio
2.21
52W high
$3.27
52W low
$1.00
Volume
7,88,577
Beta
1.47
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Traws Pharma, Inc. share price today?
- Traws Pharma, Inc. (TRAW) last traded around $1.49 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TRAW have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TRAW. Download the app for real-time alerts.
- How can I analyze Traws Pharma, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.